The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/ Lmo2) has distinct functions in erythropoiesis and in Tcell leukemogenesis. Additional functions for RBTN2 are indicated by its expression in non-hematopoietic tissues. These diverse functions of RBTN2 are presumed to be accomplished through physical interaction with dierent protein partners that bind the LIM domains of RBTN2. To identify these proteins which may modulate the activity of RBTN2, a human cDNA library was screened using the yeast two-hybrid assay. Using the RBTN2 LIM domain region as`bait', the retinoblastoma-binding protein 2 (RBP2) was identi®ed as a partner for RBTN2. The interaction between RBTN2 and RBP2 was con®rmed using in vitro binding assays, and by coimmunoprecipitation of the two proteins. Deletion analysis showed the second LIM domain of RBTN2 was necessary and sucient for binding to the last 69 amino acids of RBP2. The interaction between RBTN2 and RBP2 had a functional consequence: the combination of RBP2 and RBTN2 gave higher transcription in vitro, than RBTN2 alone. The interaction with RBP2 suggests two additional functions for RBTN2: (i) RBTN2 may directly aect the activity of RBP2, and/ or (ii) RBTN2 may indirectly modulate the functions of the retinoblastoma protein by binding to RBP2.
Introduction
Rhombotin-2 (RBTN2/TTG-2/Lmo2) is a small cysteine-rich protein with multiple functions. The ®rst function discovered for RBTN2 was that of a protooncogene in T-cells. Initially, the evidence for this conclusion was based on the high frequency of nonrandom chromosomal translocations involving the RBTN2 locus (at 11p13) in childhood T-cell acute lymphoblastic leukemia (T-ALL) (Boehm et al., 1991; Royer-Pokora et al., 1991) . These translocations result in high expression of RBTN2 in T-cells (Royer-Pokora et al., 1991; Foroni et al., 1992) in which RBTN2 is not normally expressed (Neale et al., 1995a) . More recent evidence has come from transgenic mice studies where enforced expression of RBTN2 in T-cells causes T-cell lymphoma and leukemia (Larson et al., 1994 (Larson et al., , 1995 Neale et al., 1995b) . Indeed, RBTN2 acts as a protooncogene only in T-cells (Neale et al., 1995b) where its expression results in expansion of immature CD4-CD8-thymocytes prior to overt leukemia/lymphoma (Larson et al., 1995; Neale et al., 1995b) .
A second function for RBTN2 has been found in erythropoiesis. Homozygous null mice lacking RBTN2 die in utero around day 11 due to lack of red blood cells in the embryonic yolk sac . The phenotype of RBTN2 null mice is very similar to mice de®cient for the erythroid transcription factors tal-1 (Robb et al., 1995; Shivdasani et al., 1995) or GATA-1 (Pevny et al., 1991) . Most recently, protein complexes containing RBTN2, tal-1 and GATA-1 or GATA-2 have been identi®ed , strengthening the importance of RBTN2 in erythropoiesis, and pointing to a direct role for RBTN2 in transcriptional regulation of erythroid development. Consistent with the premise that RBTN2 functions in transcriptional regulation are data showing RBTN2, when fused to a DNA binding domain, has inherent weak transcriptional activity in vitro (Sanchez-Garcia et al., 1995) . Thus, it seems likely that one function of RBTN2 is to enhance transcription when complexed with transcription factors.
However, in addition to the known functions of RBTN2, other roles for this protein are inferred from its pattern of expression (Foroni et al., 1992; Neale et al., 1995a) . RBTN2 is widely expressed in all tissues with the exception of T-cells. This would argue that function(s) exist for RBTN2 which are not involved in hematopoiesis. In addition, the location of RBTN2 within cells is variable; RBTN2 is found predominantly in the nucleus or in the cytoplasm depending upon both the tissue and the cell type (Neale et al., 1995a) . The cytoplasmic location of RBTN2 in the kidney contrasts strongly with its nuclear location in haematopoietic cells, and suggests function(s) for RBTN2 distinct from those of transcription. Indeed, the overall pattern of RBTN2 expression (Neale et al., 1995a) is highly similar to that of the acute phase response protein metallothionein-1 (Karin, 1985) , suggesting RBTN2 may play a role in the inflammatory response to injury.
How might RBTN2 accomplish its multiple functions? An important clue arises from its primary structure. The RBTN2 gene encodes a 158 amino acid protein, two-thirds of which is occupied by tandemly repeated cysteine-rich zinc-binding motifs called LIM domains. The LIM domain was originally identi®ed in the transcription factors lin-11 (Freyd et al., 1990) , isl-1 (Karlsson et al., 1990) and mec-3 (Way and Chal®e, 1988) , and subsequently in at least 18 proteins (reviewed in Sanchez-Garcia and Rabbitts, 1994) . However, unlike the LIM-homeodomain transcription factors, RBTN2 has no identi®able DNAbinding motif. Each LIM domain comprises two zinc ®ngers whose structural and functional integrity is maintained through coordination with zinc (Kosa et al., 1994; Michelsen et al., 1993) . Recently, the LIM domain has been shown to facilitate a variety of protein-protein interactions (Sadler et al., 1992; Schmeichel and Beckerle, 1994; Osada et al., 1995) . In vitro studies have shown that the LIM domain can homodimerize with another LIM domain; a single LIM domain is sucient to support this interaction (Schmeichel and Beckerle, 1994) . Indeed, it is postulated that RBTN2 dimerizes with tal-1 (ValgeArcher et al., 1994) and with itself through its LIM domain motifs.
Since it appears likely RBTN2 functions via proteinprotein interactions, one important way to understand the function of RBTN2 is to isolate its protein partners. Identi®cation and characterization of RBTN2-interacting proteins will provide insight into the mechanisms of action of RBTN2, and the cellular pathways it may in¯uence. To iden®ty these proteins we employed the yeast two hybrid assay to screen a human cDNA library using the LIM domains of RBTN2 as`bait'. A strongly interacting clone isolated from the library was found identical to the carboxyterminal region of the retinoblastoma-binding protein-2 (RBP2). Further experiments using full-length RBP2 indicated that RBP2 speci®cally interacts with the second LIM domain of RBTN2, and that RBP2 modulates the transcriptional activity of RBTN2. The net eect of the interaction between RBTN2 with RBP2 within the cell may result directly in altered RBP2 function, or indirectly via altered retinoblastoma protein (Rb) function.
Results

Identi®cation of RBP2 as the interacting partner of RBTN2
The yeast two-hybrid system was designed to study protein-protein interaction in vivo (Fields and Song, 1989) , and relies upon fusion of a`bait' protein to the DNA binding domain of the yeast Gal4 protein. Initial attempts using the full-length RBTN2 coding sequences as bait were unsuccessful since RBTN2 contains intrinsic transcriptional activity (Sanchez-Garcia et al., 1995) and gave rise to positive clones in the absence of activation domain clones. To circumvent this problem we constructed deletion mutants of RBTN2 and fused them with the Gal-4 DNA-binding domain (GBD) to remove the intrinsic transcriptional activity. We chose one construct, pAS2-R2L12, which contained only the LIM domain region of RBTN2 (Figure 1 ) as the bait in our screening since this construct did not display any transcriptional activity, yet contained both LIM domain sequences intact. The pAS2-R2L12 construct and a human cDNA library cloned in pACT (Durfee et al., 1993) were cotransformed in yeast Y190 which contains the reporter genes his3 and lacZ under the control of Gal4 regulatory sequences. The transformants (total 1.4610 6 ) were placed under growth selection for histidine production followed by ®lter-lift assay for bgal activity. Only clones which were positive by both criteria were pursued. To eliminate false positives arising from non-speci®c interaction of library proteins with the Gal-4 DNA-binding domain or to the Gal-4 sequences upstream of the reporter constructs, yeast mating assays (Harper et al., 1993) were also performed. Yeast strain Y190 containing the segregated positive pACT library clone was mated with strain Y187 transformed with non-related control GBD fusions: pAS2-CYB, pAS2-lamin, or pAS2-SNF1. The cDNA library clones which were positive after mating with the control fusion proteins were considered falsepositive and eliminated. Among the`true' positive clones remaining, only those strongly positive by b-gal assay were selected for further studies.
A strong positive clone, pACT-c145, was isolated. Sequence analysis revealed the 1 kb insert of pACT- Figure 1 Schematic diagram of structural motifs of RBTN2, and the deletion constructs used in experiments. The LIM1, LIM2, and amino-terminal activation (Act) domains are shown c145 matched the 3'-sequence of the retinoblastomabinding protein-2 (RBP2) gene (Defeo-Jones et al., 1991) , and encoded the last 69 amino acids of RBP2 in frame with the Gal 4 DNA binding domain ( Figure  2a ). To con®rm the interaction between pACT-c145 and pAS-R2L12, the individual plasmids were isolated, and then co-transformed into yeast Y190. The resultant transformants were both his + and b-gal + (data not shown), con®rming the interaction between the LIM domain region of RBTN2 (R2L12) and the C-terminal fragment of RBP2 in yeast.
RBP2 interacts with the second LIM domain of RBTN2
Yeast mating assays were performed to investigate whether the interaction between the RBP2 clone was dependent on both LIM domains of RBTN2. Deletion constructs of RBTN2 ( Figure 1 ) were made in pAS2 and transformed into yeast strain Y187. The resulting Y187 strains were mated with strain Y190 containing pACT-c145 and then assayed for growth in the absence of histidine and for b-gal activity ( Figure 3 ). As negative controls, Y187 strains containing the nonrelated fusion plasmids pAS2-lamin, pAS2-SNF1, and pAS2-CyB were also mated with Y190/pACT-c145. Positive growth and b-gal activity were seen only when Y190/pACT-c145 was mated with Y187/pAS2-R2L12 or Y187/pAS2-R2L2, but not with Y187/pAS2R2L1 or the negative controls. These results con®rmed the cotransformation assays in yeast Y190, and indicated the interaction between the RBP2 clone and RBTN2 was speci®c for the second LIM domain of RBTN2.
In vitro interaction of RBP2 and RBTN2
We examined whether the interaction between RBTN2 and RBP2 observed in vivo in yeast could be demonstrated by in vitro binding assays. The 1 kb cDNA insert from pACT-c145 was sub-cloned into pGEX-4T2 to produce a fusion protein containing gluathione-S-transferase (GST) joined to the C-terminal region of RBP2 (GST-c145). The expression and size of this fusion protein produced in E. coli was con®rmed by SDS ± PAGE (data not shown). GST proteins were conjugated to glutathione sepharose beads and then incubated with 35 S-labeled in vitro-translated RBTN2. After incubation, the beads were washed and then boiled in gel loading buer to detect bound To more vigorously examine the interaction between RBTN2 and RBP2, we attempted to co-immunoprecipitate the two proteins. The plasmid pCMV-RBP2, containing the full length cDNA of RBP2 was used to construct a NIH3T3 cell line (3T3/RBP2) expressing high levels of exogenous RBP2. Extracts were made from 3T3/RBP2 cells and incubated with in vitrotranslated 35 S-RBTN2. The mixture was then subjected
Figure 3 RBP2 speci®cally interacts with the second LIM domain of RBTN2. Yeast mating assays were performed using Y190/pACT-c145 and Y187 strains expressing GAL4 fusion proteins. Growth selection was on SD-Trp-Leu plus 50 mM 3AT plates containing X-Gal to select for both histidine production and lacZ activation. Y187 strains contained: pAS2-R2L12, expressing both LIM domains of RBTN2; pAS-R2L1, expressing the ®rst LIM domain of RBTN2; pAS2-R2L2, expressing the second LIM domain of RBTN2; or controls (pAS2-lamin, pAS2-SNF1, and pAS2-CyB) to immunoprecipitation using rabbit anti-RBP2 antiserum (Fattaey et al., 1993) or rabbit anti-RBTN2 antiserum (Neale et al., 1995a) , and analysed by SDS ± PAGE ( Figure 5 ). As expected, S-RBTN2 signal was also detected using anti-RBP2 antiserum ( Figure 5 , lane 2), indicating that RBTN2 was coimmunoprecipitated with RBP2. Not all of the RBTN2 in the assay was recovered using anti-RBP2 antiserum ( Figure 5 , compare lanes 2 and 3), suggesting either (i) there was insucient RBP2 in the assay to complex all available RBTN2, or (ii) if sucient RBP2 existed, not all RBP2 could bind to RBTN2. The co-immunoprecipitation of RBTN2 using anti-RBP2 antiserum was dependent upon RBP2 since 35 S-RBTN2 was not detected in the absence of RBP2 extracts ( Figure 5 , lane 5). In addition, a faint 35 S-RBTN2 signal was also seen when anti-RBP2 antiserum was used to immunoprecipitate mixtures containing lysates from untransfected NIH3T3 cells ( Figure 5 , lane 6). This signal presumably re¯ected co-immunoprecipitation of RBTN2 with endogenously expressed RBP2. Overall, these data substantiated those obtained in yeast, and strongly support the existence of complex between RBTN2 and RBP2.
In vivo interaction of RBTN2 and RBP2
To demonstrate an in vivo interaction between RBTN2 and RBP2, we attempted to co-immunoprecipitate the two proteins radiolabeled in vivo. MEL cells which express a high amount of RBTN2 (data not shown) were labeled with [ 32 P]orthophosphate for 4 h, and cell lysates were immunoprecipitated using either anti-RBTN2 antisera, or anti-RBP2 antisera (Figure 6a ). Anti-RBP2 antisera (Figure 6a , lane 3) immunoprecipitated two bands (*200 kDa) as previously reported (Fattaey et al., 1993) . These two bands, not detected In these experiments, both anti-RBTN2 and anti-RBP2 antisera also immunoprecipitated other bands from the radiolabeled cell extracts. It remains to be established whether these proteins represent speci®c interactions and/or non-speci®c background. Overall, the data presented in Figure 6 suggest that RBTN2 and RBP2 physically associate with each other in vivo.
Increased transcription is a functional consequence of the RBTN2-RBP2 interaction As discovered initially through our two-hybrid screen, and independently by others (Sanchez-Garcia et al., 1995) RBTN2 has transcriptional activation activity, and this activity is located within the N-terminal region. Since our ®ndings indicated a physical interaction between RBP2 and RBTN2, we investigated whether this interaction could in¯uence the transcriptional activity of RBTN2. The entire RBTN2 coding sequence was subcloned into the mammalian GBD fusion vector pM3 to make the construct pM3-R2. The pM3-R2 plasmid was then co-transfected with the chloramphenicol acetyl transferase (CAT) reporter gene construct pG5EC, along with the pCMV-b-gal plasmid into COS cells expressing RBP2 (COS/RBP2). Forty-eight hours post-transfection, cell extracts were made and analysed for CAT activity or b-galactosidase activity. Similar to Sanchez-Garcia et al. (1995) , we found that RBTN2 possesses weak transactivation activity. In several experiments, RBTN2 transfected cells showed three-to sixfold increase in CAT activity as compared to control (vector alone) transfected cells. Representative data from one of these experiments are shown in Figure 7 . The CAT activity due to expression of RBTN2 in COS cells was signi®cantly higher than background level (Figure 7, compare lanes 1 and 2) . Quantitation using a phosphoimager revealed a 5.7-fold increase in CAT activity relative to background. When pM3-R2 construct was transfected into COS cells expressing high amount of RBP2 (COS/RBP2), we observed higher CAT activity relative to that seen in COS cells alone (Figure 7, compare lanes 2 and 4) . When quantitated, the CAT activity in COS/RBP2 cells (lane 4) was 2.5-fold higher as compared to COS cells alone (lane 2), and 14.7-fold higher as compared to COS/RBP2 cells transfected with vector alone (lane 3). The relative CAT activities in these experiments were very reproducible from one experiment to another. A two-to threefold enhancement of transcription activity was also detected in NIH3T3 cells (data not shown).
Discussion
The proto-oncogene RBTN2 has multiple roles. Two of these roles are currently known; one is in erythropoiesis , while the other is in T-cell leukemogenesis (Larson et al., 1994 (Larson et al., , 1995 Neale et al., 1995b) . In addition, other roles for RBTN2 are inferred from its expression in nonhematopoietic tissues (Neale et al., 1995a) . A strong clue to how RBTN2 participates in these many roles is provided by examination of its primary structure: RBTN2 has two LIM domain motifs. The zinc-®nger motif of the LIM domain appears to be a somewhat promiscuous protein binding structure since several dierent types of proteins have been found to interact with this motif (Feuerstein et al., 1994; Schmeichel and Beckerle, 1994; Valge-Archer et al., 1994) . Thus, thē exibility of RBTN2 to carry out its dierent functions would be conferred by binding dierent protein partners via its LIM domains. Indeed, in erythroid cells it appears that RBTN2 binds simultaneously to several erythroid transcription factors , presumably to make an active complex. Thus, it is likely in non-erythroid cells that RBTN2 binds a dierent complement of proteins which have nonerythroid functions. From our yeast two-hybrid screen, we have identi®ed the retinoblastoma binding protein 2 (RBP2) as a partner for RBTN2. RBP2 is ubiquitously expressed among tissues (Fattaey et al., 1993) , and binds (Defeo-Jones et al., 1991) the SV40 T antigen/adenovirus E1A (T/E1A) pocket of the retinoblastoma protein (Rb) through the LXCXE motif which is conserved among Rb-binding proteins (Riley et al., 1994) . RBP2 preferentially interacts with the hypo-phosphorylated form of Rb, and contains two dierent domains which interact with Rb, (i) the LXCXE motif which is associated with the T/E1A pocket of Rb and p107
Rb ; and (ii) a non-T/E1A binding domain which selectively binds to Rb and the TATA box-binding protein (TBP), but not p107
Rb (Kim et al., 1994) . Thus, one function for RBP2 may be modulation of Rb activity during the cell cycle.
While the speci®c function for RBP2 remains elusive, considerable information suggests that RBP2 is a transcription factor. First, RBP2 is found exclusively in the nucleus in a wide variety of tissues (Fattaey et al., 1993) . Second, sequence analysis shows that RBP2 contains a region homologous to the homeobox domain of the engrailed family of homeotic genes and a potential zinc-®nger domain close to the N-terminus (Fattaey et al., 1993; Kim et al., 1994) . Third, in vitro translated RBP2 can be selectively retained on immobilized calf thymus DNA under relatively high salt concentration (Fattaey et al., 1993) . Taken together, these data strongly support the function of RBP2 to be that of a transcription factor. In addition, the interaction between RBP2 and TBP (Kim et al., 1994) , an essential component of general transcriptional machinery (Rowlands et al., 1994) , is further evidence that RBP2 functions as a transcription factor.
In addition to binding Rb and TBP, our data show that RBP2 also binds to RBTN2. The binding between RBP2 and RBTN2 is domain-speci®c: the second LIM domain of RBTN2 interacts with the Cterminus of RBP2. Our data from interaction assays in yeast, and in vitro transactivation assays in COS cells, show that the second LIM domain of RBTN2 is both necessary and sucient to bind RBP2. These data con®rm a previous ®nding that a single LIM domain is sucient for protein-protein interactions (Schmeichel and Beckerle, 1994) . The region of RBP2 which binds to RBTN2 is located within the last 69 amino acids of RBP2. This region is de®ned by the cDNA clone isolated from the yeast two-hybrid assay, and was con®rmed by in vitro binding assays. The carboxyl 69 amino acids of RBP2 are cysteine-and histidine-rich, with spacing between these residues suggestive of an atypical zinc ®nger motif. This atypical zinc-®nger could be the structural basis for the interaction of RBP2 with RBTN2, and would represent a third motif which interacts with the LIM domain. The LIM domain has already been shown to interact with the HLH motif (German et al., 1992) , and with other LIM domains (Feuerstein et al., 1994; Schmeichel and Beckerle, 1994) . Further studies are necessary to identify the critical residues within each of the cysteine-rich motifs of RBTN2 and RBP2 that are involved in protein-protein interaction. Interestingly, the RBTN2-binding region of RBP2 is remote from both the LXCXE motif and the non-T/E1A binding region (Figure 2b) . Thus, potentially, RBP2 could bind RBTN2 independently, or in addition to Rb or TBP.
By similarity search, the RBTN2-binding region of RBP2 was found highly homologous to a cysteine-rich zinc-®nger region called LAP (Leukemia-associatedprotein) domain (Saha et al., 1995) or PHD ®nger (Aasland et al., 1995) (Figure 2c ). RBP2 has three LAP domains (Figure 2b ). The LAP motif is found in a variety of proteins, including some leukemiaassociated fusion proteins, and the Drosophila trithorax gene TRX (Mazo et al., 1990) and its human homolog HRX (Tkachuk et al., 1992) . The TRX gene is involved in maintenance of homeotic gene expression in Drosophila (Kennison, 1993) , while the human HRX gene was originally identi®ed through a variety of chromosomal abnormalities involving chromosome 11q23 in childhood leukemia (Tkachuk et al., 1992; Gu et al., 1992) . As found in children with multiple lineage acute leukemia, the LAP motif of HRX is invariably lost by chromosomal changes on 11q23 ; loss of this region is thought to contribute to the pathogenesis of these leukemias. Removal of LAP motif function, by either chromosomal translocation or protein fusion in acute leukemias, presumably results in protein deregulation and promotes leukemogenesis. While the exact role of the LAP motif is still unknown, our data showing RBTN2 binding to a LAP motif within RBP2 suggests a protein binding function for this motif. Thus, our data suggest another mechanism by which LAP function may be lost; interaction with a partner, such as RBTN2, which is inappropriately expressed during leukemogenesis.
We observed a functional consequence to the interaction between RBP2 and RBTN2. When tested using in vitro transcription assays, the addition of RBP2 resulted in increased transcription of the CAT reporter gene construct over that of RBTN2 alone. The increased transcription activity is not restricted to COS cells, because similar enhancement was seen in NIH3T3 cells (data not shown). This enhancement of transcription could be achieved by two means: (i) interaction of RBP2 with RBTN2 enhances the transactivation activity of RBTN2, or (ii) RBP2 has intrinsic transactivation activity which is detected when interacting with RBTN2 in our in vitro assay. In either case, the net eect of the interaction results in increased transcriptional activity in vitro, and thus, an in vivo interaction between RBTN2 and RBP2 may have similar consequence.
There are two possible physiological outcomes to the interaction between RBTN2 and RBP2. The ®rst is a direct aect of RBTN2 on the function of RBP2. The second is an indirect aect of RBTN2 on the function of Rb through binding to RBP2. These outcomes are not mutually exclusive, and RBTN2 may function through a combination of these eects.
Rb is a tumor suppressor protein, and plays a central role in the control of cell division and the entry into S phase in mammalian cells. In addition, it is also critical in the development and dierentiation of certain cell types (Riley et al., 1994; Weinberg, 1995) . Various proteins including transcription factors which are important in these processes, like E2F, ATF-2, and MyoD, interact with and are regulated by the hypo-phosphorylated form of Rb during G 1 (Riley et al., 1994; Dunaief et al., 1994 ). RBP2 appears to be another transcription factor which interacts with the T/E1A pocket of hypo-phosphorylated Rb. However, since the speci®c function of RBP2 is not yet known, it is not possible to speculate what cellular processes may be in¯uenced by interaction with RBTN2. However, our results show that interaction between these two proteins results in enhanced transcriptional activity in vitro. Since RBTN2 has no known DNA-binding motif, it seems likely that such an interaction would enhance transcription of RBP2-regulated genes, whether they be linked to proliferation or dierentiation.
Our demonstration of the physical association between RBP2 and RBTN2 suggests a physical or physiological link may also exist between Rb and RBTN2. It is interesting to note that both RBTN2 and Rb have essential roles in erythropoiesis. Both Rbde®cient mice (Clarke et al., 1992; Lee et al., 1992) and RBTN2-de®cient mice die very early during embryogenesis through lack of erythropoiesis. Since RBTN2-de®cient mice die several days earlier than Rb-de®cient mice it might suggest, if a link exists between these proteins, that the role of RBTN2 during erythropoiesis would be upstream to that of Rb.
RBP2 is the ®rst non-erythroid partner identi®ed for RBTN2. RBTN2 is known to interact with the erythroid transcription factors tal-1, GATA-1, and GATA-2 (Wadman et al., 1994; Osada et al., 1995) . Since RBTN2 has no demonstrable DNA-binding activity, it has been postulated that RBTN2, by binding its cognate partners, modulates their transcription activity. The data presented in this paper provide direct support for this hypothesis; the interaction between RBTN2 and RBP2 results in increased transcription activity. It is likely that interaction of RBTN2 with transcription factors tal-1, GATA-1 and GATA-2 also aects their transcription activity. Our ®ndings indicate that RBTN2 most likely performs its multiple functions by modifying the activity of a variety of transcription factors.
Materials and methods
Cell lines and transfections
COS-1, NIH3T3, and MEL cells were grown in Dulbecco's modi®ed Eagle's medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. COS-1/RBP2 cell cultures and NIH3T3/RBP2 cell cultures were established by transfecting the parental cell lines with plasmid pCMV-RBP2 and selecting for resistance to G418. COS-1/RBP2 and NIH3T3/RBP2 cell cultures were maintained in the above medium supplemented with 400 mg/ml G418 (Life Technologies, Gaithersburg, Maryland).
All transfections were performed using lipofectamine reagent (Life Technologies) as described by the supplier. Expression of RBP2 in COS-1/RBP2 and NIH3T3/RBP2 cell cultures was con®rmed by Western blot analysis using anti-RBP2 antiserum.
Antisera
The anti-RBTN2 antiserum was generated in rabbits using a synthetic peptide corresponding to the N-terminus of RBTN2 and anity puri®ed as described (Neale et al., 1995a) . Anti-RBP2 antiserum (kindly supplied by Drs Alan Oli and Debora Defeo-Jones, Merck Research Laboratories, West Point, Pennsylvania) was generated in rabbits against the C-terminal 290 amino acids of human RBP2 fused with glutathione-s-transferase (GST) as described (Fattaey et al., 1993; Kim et al., 1994) , and was absorbed twice with GST-sepharose before use.
Plasmids
All RBTN2 clones and deletion mutants were generated by PCR, cloned into the appropriate fusion vector (pAS2 or pM3), and then sequenced fully to verify ®delity of the PCR. The full length mouse RBTN2 cDNA is 158 amino acids. Deletion constructs (Figure 1) used were: LIM domain region (R2L12, amino acids 27 ± 150); ®rst LIM domain region (R2L1, amino acids 27 ± 86); second LIM domain region (R2L2, amino acids 92 ± 150). Yeast vectors expressing Gal4 DNA-binding domain fusions were generated by ligating PCR-produced cDNAs into the NcoI site of pAS2 (Harper et al., 1993) . The pGEX/c145 construct was generated by ligating the 1 kb cDNA insert from clone pACT-c145 into the XhoI site of pGEX4T2 vector (Pharmacia Biotech Inc., Piscataway, New Jersey). Mammalian vectors expressing Gal4 DNA-binding domain fusions were generated by ligating PCR-produced cDNAs into the HindIII site of pM3 (Sadowski et al., 1992) . The CAT reporter gene vector pG5EC has been described previously (Sadowski et al., 1992) . The pCMV-RBP2 plasmid (a generous gift from Drs Alan Oli and Debora Defeo-Jones) contains the full length coding region of human RBP2 under control of the CMV promoter (Kim et al., 1994) . The pBS/R2 construct (Neale et al., 1995b) contains the entire coding sequence of RBTN2 under control of the T7 promoter in pBluescript (Stratagene, La Jolla, California). The pCMV-b-gal plasmid (Clontech, Palo Alto, California) contains the b-galactosidase gene under control of the CMV promoter.
Yeast strains
The yeast strain Y190 is (MATa, gal4Dgal80D URA3 GAL-lacZ, LYS GAL-HIS3, cyh r ); strain Y187 (MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GALlacZmet 7 ) is the opposite mating type of Y190. Both strains were supplied by Dr Stephen Elledge (Baylor College of Medicine, Houston, Texas) and grown on YPAD medium, or SD minimal medium supplemented as described (Harper et al., 1993) .
Two-hybrid screening
The general procedure of library screening by the twohybrid interactive assay was performed as described (Harper et al., 1993) . A human lymphocyte cDNA library constructed in pACT was generously provided by Dr Stephen Elledge. Twenty micrograms of pAS2/R2L12 and 20 mg of pACT-cDNA library were co-transformed into yeast strain Y190. The transformants (1.4610 6 ) were selected for growth on minimal media lacking histidine, leucine, and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies were then screened for b-galactosidase by ®lter lift assay. The double-positive colonies (His + , b-gal + ) were then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/ R2L12 plasmids but retention of pACT-cDNA library plasmids. The resulting Y190 strains were mated with Y187 strains expressing R2L12 or the non-related control proteins cyclophilin B (Bram et al., 1993) , lamin (Harper et al., 1993) , or SNF1 (Harper et al., 1993) as Gal4 fusions as described (Harper et al., 1993; Bram et al., 1993) , and screened for b-galactosidase by ®lter lift assay. Yeast clones that were b-gal + after mating with the control Gal4 fusions were considered false positives.
Preparation of 35 S-labeled RBTN2
35 S-labeled RBTN2 was prepared from plasmid pBS/R2 using an in vitro transcription/translation kit (Promega, Madison, Wisconsin) and [ 35 S]cysteine (Amersham, Arlington Heights, Illinois) as described by the suppliers.
In vitro binding assays
The cDNA insert from clone pACT-c145 was expressed as a GST fusion protein in E. coli using the construct pGEX/ c145 and puri®ed as described (Ausebel, 1993) . The pGEX/ c145 fusion protein was bound to sepharose beads by incubation with 20 ml of 50% glutathione sepharose beads for 30 min at 48C. After washing three times with NETN buer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40), the bound beads were incubated with 5 ml of in vitro translated RBTN2 with gentle rocking for 1 h at 48C. The beads were then washed six times with cold NETN buer, and the bound proteins were separated by SDS ± PAGE and visualized by¯uorography.
In vitro co-immunoprecipitation assays
Cell lysates were made from NIH3T3/RBP2 or NIH3T3 cultures by the following method. Con¯uent cells in 10 cm dishes were washed twice with cold PBS and then scraped into a microfuge tube. After centrifugation at 1000 g for 4 min, the cell pellet was resuspended in 1 ml RIPA buer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mg/ml aprotinin, 1 mM PAFABLOC (Boehringer Mannheim), 2 mg/ml leupeptin) and incubated on ice for 30 min. Insoluble debris were removed by centrifugation at 14 000 g for 10 min at 48C, and the supernatant stored at 7808C. For co-immunoprecipitation assays, 100 ml of cell lysate was mixed with 5 ml of in vitro translated [
35 S]RBTN2. The mixture was precleared by incubation with Protein A sepharose beads, and then incubated with the appropriate rabbit serum for 60 min at 48C. The antisera used were anti-RBP2 antiserum, anti-RBTN2 antiserum or preimmune serum. Fifty ml of 10% Protein A sepharose beads were then added, and the incubation continued for a further 60 min at 48C. The sepharose beads were then washed twice with RIP buer (50 mM Tris pH 8.0, 1 mM EDTA, 150 mM NaCl) containing 0.25% bovine serum albumin, and then twice with RIP buer containing 0.1% Triton X-100. The washed beads were then heated at 958C for 5 min in gel loading buer, and then loaded onto a 12% SDS-polyacrylamide gel. After electrophoresis, gels were soaked for 30 min in 16% sodium salicylate, then dried prior to autoradiography.
In vivo co-immunoprecipitation assays 35 S-and 32 P-labeled extracts were prepared from the mouse erythroleukemia cell line MEL by resuspending exponentially growing cells (5610 7 cells) in growth medium lacking cysteine or phosphate, respectively. After incubation with 100 mCi/ml [ 35 S]cysteine or 1 mCi/ml [ 32 P]orthophosphate (Amersham) for 4 h, cells were washed and extracts prepared as described above. In experiments designed to co-immunoprecipitate RBTN2, a portion of the 35 S-labeled extract (1610 7 incorporated c.p.m.) was immunoprecipitated with antisera against RBP2, and analysed on 12% SDS-polyacrylamide gels as described above. In experiments designed to co-immunoprecipitate RBP2, a portion of the 32 P-labeled extract (4610 7 incorporated c.p.m.) was immunoprecipitated with antisera against RBTN2, and analysed on 8% SDS-polyacrylamide gels as described above.
CAT assays
Two micrograms of the CAT reporter construct pG5EC were co-transfected with 2 mg of either pM3 or pM3/R2 into COS-1 and COS-1/RBP2 cells. Transfection eciency within each experiment was measured by co-transfection of 2 mg of pCMV-b-gal plasmid. The amount of cell lysate used in each CAT assay was adjusted based on the bgalactosidase activity of each extract. CAT activity was assayed as described (Ausebel, 1993) followed by autoradiography. Quanti®cation of CAT activity was performed using a phospho-imager (Molecular Dynamics, Sunnyvale, California) and the associated software ImageQuant.
